A delayed immune event: a drug that stopped months ago
Educational use only. Not clinically reviewed63-year-old man for calm exposure recording, evidence-boundary review, escalation to the treating service, and handoff practice. About 9 simulated minutes.
What you will practise
- Record a completed exposure as current history.
- Recognize that the interval since the last dose does not exclude the drug.
- Record infection evaluation as running alongside rather than ahead.
- Return the problem to the service holding the treatment record.
- Record bounded qualified-team treatment intent without selecting treatment.
- Review the boundaries and their certainty.
- Hand off an exposure that must travel with the patient.
Review and sources
Not clinically reviewed. No clinician has signed this scenario.
- Couey MA, Bell RB, Patel AA, et al. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer. 2019;7(1):165. DIRE defined as new immune-related adverse events manifesting 90 days or more after discontinuation; 23 qualifying cases; median off-treatment interval to DIRE 6 months (range 3 to 28); median cumulative exposure 4 doses (range 3 to 42); misattribution can lead to unnecessary or harmful interventions.
- Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435. Immune-related adverse events can occur at any point during or after cessation of treatment, beyond 6 to 12 months. Diagnostic evaluation should attempt to rule out other etiologies, such as diarrhea or colitis associated with Clostridium difficile infection, but treatment for immune-related adverse events should be initiated as is deemed clinically appropriate. Additional workup at grade 2 or above includes stool infectious analysis with C. difficile and cytomegalovirus testing by polymerase chain reaction.
- Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4(12):1721-1728. Of 193 reported anti-CTLA-4 deaths, 135 (70%) were usually from colitis; colitis itself carried reported fatalities of only 2% to 5%; anti-PD-1/PD-L1 fatalities were more often pneumonitis, hepatitis, and neurotoxic effects.
Open Sim Lab is an educational simulator, not for clinical use. It is not a clinical decision-support tool, not a dosing calculator, and is not validated for any decision affecting a real patient.